selective estrogen receptor modulator (SERM)
Jump to navigation
Jump to search
Introduction
A term used for modulators of the estrogen receptor
- tamoxifen (estrogen receptor antagonist)
- raloxifene (mixed estrogen receptor antagonist/agonist)
- toremifene
Indications
- preventive effects against breast cancer up to 5 years after therapy ends[1]
- effect mostly due to reductions in estrogen receptor- positive breast cancer
- endometrial cancer[2]
- ovarian cancer
- osteoporosis
- atrophic vaginitis[2]
Adverse effects
More general terms
More specific terms
- bazedoxifene
- ospemifene (Osphena)
- raloxifene (Evista)
- tamoxifen (Novaldex, Soltamox)
- toremifene (Fareston)
Additional terms
References
- ↑ 1.0 1.1 Cuzick J et al Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. The Lancet, Early Online Publication, 30 April 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23639488 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60140-3/abstract
- ↑ 2.0 2.1 2.2 Deprecated Reference